Whole-Body Hormone Health and Integrative Approaches

Integrative Hormone Health, Iron Physiology, and Evidence-Based Care

Abstract

In this educational post, I walk you through an integrative, evidence-based journey across several clinical topics that frequently intersect in real-world practice: iron physiology and clinical decision-making; hormonal contraceptives and progestin families; intrauterine devices (IUDs) and risk considerations; progesterone strategies for patients with PCOS and sensitivity to hormones; practical cortisol, thyroid, and ferritin interpretation; male fertility support and short-term selective estrogen receptor modulators; breast health, receptor positivity, and nuanced conversations around DCIS; post-TIA hormone considerations; estriol/estradiol formulation choices; and thyroid optimization in Hashimoto’s. I also highlight how integrative chiropractic care complements endocrine and metabolic treatment by addressing biomechanical stress, autonomic tone, and neuroimmune crosstalk—key physiological drivers of absorption, inflammation, and hormone signaling. The goal is to give you a clear, practical framework for safer, personalized, and outcome-focused care.

Identity, Health Trajectories, and Why Choice Matters

I often begin by acknowledging that many of us carry more than one identity—parent, professional, athlete, caregiver—and our health choices should empower those identities rather than shrink them. In my clinical work, I emphasize patient agency: we co-define priorities, risks, and benefits; we anchor treatment decisions to measurable outcomes; and we iterate based on data. In hormone and iron management, the ability to choose—and to understand the physiology behind that choice—reduces anxiety, improves adherence, and increases safety.

Key takeaways:

• Your identities influence your health goals, risk tolerance, and preferences.
• Informed choice improves adherence and outcomes.
• Shared decision-making should be anchored in objective data and symptom tracking.

Iron Physiology, Ferritin, and Clinical Reasoning

When patients ask me about iron—especially serum iron and serum ferritin—my first step is to explain iron’s core physiology. Ferritin is a storage protein reflecting iron reserves; transferrin transports iron; and hemoglobin integrates iron into oxygen transport. Serum iron varies with meals and diurnal rhythms, while ferritin more reliably reflects stores, though it is also an acute-phase reactant that rises in inflammation.

Why ferritin thresholds matter:

• Ferritin under about 30 ng/mL often correlates with depleted iron stores and may cause fatigue, hair thinning, brittle nails, and reduced exercise capacity (Camaschella, 2019).
• In athletes and menstruating individuals, ferritin under 50 ng/mL can impair performance and increase symptoms (DellaValle, 2013).
• Elevated ferritin with normal transferrin saturation frequently signals inflammation rather than iron overload.

Physiological underpinnings:

• Low ferritin reflects insufficient iron availability for erythropoiesis and mitochondrial function, impairing ATP production and inducing compensatory catecholamine stress.
• Inflammation increases hepcidin, trapping iron in macrophages and reducing absorption; this results in functional iron deficiency despite adequate intake (Ganz & Nemeth, 2012).

Integrative assessment:

• Identify causes: dehydration, malabsorption (celiac, SIBO, hypochlorhydria), hemorrhage, GI blood loss, and gynecologic bleeding.
• Screen special populations: neonates can experience the so-called “pink hour,” a transient period of blood volume shifts; in all ages, evaluate oxygenation and hemodynamics during acute illness.

Clinical protocol:

• Order CBC, ferritin, transferrin saturation, CRP, and, if indicated, fecal occult blood and celiac serology.
• Treat root causes (gut dysbiosis, H. pylori, heavy menses) before or alongside iron replacement.
• If oral iron is used, consider high-bioavailability forms and alternate-day dosing to lower hepcidin spikes (Moretti et al., 2015).
• When inflammation elevates ferritin, prioritize an anti-inflammatory diet, microbiome repair, and source control over iron loading.

How integrative chiropractic fits:

• Reducing musculoskeletal pain and autonomic hyperarousal can improve GI motility and vagal tone, enhancing iron absorption and lowering inflammatory load.
• Postural support and breathing mechanics improve oxygen delivery and perceived fatigue.

References:

• Iron deficiency and related disorders (Camaschella, 2019)
• Hepcidin physiology and iron homeostasis (Ganz & Nemeth, 2012)
• Alternate-day oral iron dosing improves absorption (Moretti et al., 2015)
• Iron status and performance in athletes (DellaValle, 2013)

Understanding Progestins, IUDs, and Clot Risk

Patients regularly ask me about IUDs and progestin families. It’s crucial to distinguish between progesterone (bioidentical) and progestins (synthetic analogs), which have divergent receptor affinities and side-effect profiles.

Key distinctions:

• Levonorgestrel IUDs (e.g., Mirena) exert predominantly local endometrial effects, with minimal systemic exposure; the risk of systemic clotting is far lower than with oral progestins (ACOG, 2022).
• Progestin families (norethindrone derivatives vs. levonorgestrel derivatives) differ in androgenicity and metabolic impact (Dragoman & Gaffield, 2016).
• Bioidentical micronized progesterone has a more favorable profile for sleep, mood, and endometrial protection compared to many synthetic progestins (Prior, 2018).

Why local IUD delivery matters:

• Local progestin dampens endometrial proliferation, decreases menstrual blood loss, and reduces dysmenorrhea with less systemic exposure, thus lowering thrombotic and metabolic risks.
• Tissue-level diffusion allows surrounding tissues to buffer effects, contributing to tolerability and surgical utility in some contexts.

Clinical considerations:

• For patients with estrogen-related side effects or clot risk, levonorgestrel IUDs are often preferable due to localized action.
• Evaluate for androgenicity if acne or hair changes occur; some progestins are more androgenic than others.
• For PCOS, balance estrogen/progesterone with attention to insulin resistance and hyperandrogenism.

References:

• ACOG practice advisory on LARC safety (ACOG, 2022)
• Contraceptive progestins and health effects (Dragoman & Gaffield, 2016)
• Micronized progesterone benefits (Prior, 2018)

Progesterone Strategies for PCOS and Sensitivity

Many PCOS patients report that progesterone makes them feel unwell when the hormonal system is unstable. My approach is to personalize dosing and route while addressing the upstream drivers: insulin resistance, inflammation, and stress.

Physiology:

• PCOS is characterized by ovarian androgen excess, altered LH/FSH dynamics, and often insulin resistance. Progesterone’s CNS effects involve GABA-A receptor modulation, which can be calming but may feel dysphoric if there is neuroinflammation or cortisol dysregulation.

Clinical approach:

• Start with a low dose of micronized progesterone and titrate.
• Consider sublingual formulations for higher bioavailability and a steadier effect; in practice, 100 mg sublingual can approximate the potency of 200 mg oral.
• If a patient is sensitive, splitting troches can allow micro-titration (e.g., quartering a 200 mg troche).
• Address insulin resistance with nutrition, sleep optimization, stress management, and movement.

Why it works:

• Sublingual delivery bypasses first-pass metabolism, providing consistent neurosteroid effects with potentially fewer GI side effects.
• Treating insulin resistance reduces ovulatory dysfunction and stabilizes progesterone responses over time.

Integrative chiropractic role:

• By modulating autonomic tone through spinal adjustments and neuromuscular interventions, we support the balance of the hypothalamic-pituitary-ovarian axis and reduce stress-induced symptom flares.

Reference:

• PCOS pathophysiology and treatment (Azziz et al., 2016)

Cortisol Testing: Salivary Profiles vs. Serum Snapshots

When we ask “what is cortisol doing?” the test must match the question. Four- to five-point salivary cortisol profiles reflect diurnal rhythm and are superior for assessing HPA axis dynamics, while a single AM serum cortisol is useful for screening for insufficiency but limited for rhythm analysis.

Physiological rationale:

• Cortisol follows a robust circadian pattern, peaking in the early morning and gradually declining; stress, sleep disruption, pain, and inflammation can alter this rhythm.
• Salivary free cortisol mirrors tissue-level exposure more closely than total serum cortisol, which is influenced by binding proteins (SHBG, CBG).

Practical use:

• For fatigue, sleep issues, and stress intolerance, order a multitime salivary profile.
• For suspected adrenal insufficiency, start with AM serum cortisol and consider ACTH stimulation testing.
• Pair cortisol tests with fasting insulin/glucose and CRP to see the interplay between metabolic load and stress hormones.

Reference:

• Cortisol rhythms and assessment (Guilliams & Williams, 2016)

Male Fertility, Low T, and Short-Term Clomiphene

In men in their 20s–30s with low-normal testosterone who wish to conceive, I may use short-term clomiphene citrate (selective estrogen receptor modulator) for 3–6 months to raise endogenous LH/FSH, increase sperm count, and elevate testosterone. This is not a long-term solution and should be carefully monitored.

Why short-term SERM makes sense:

• Clomiphene blocks estrogen receptors in the hypothalamus, relieving negative feedback and increasing gonadotropin secretion, thereby supporting spermatogenesis and testicular testosterone production.
• Long-term estrogen receptor blockade is not advisable due to cardiovascular and neuroendocrine concerns.

Lifestyle first:

• In younger males, lifestyle and nutrition frequently move testosterone from ~300 ng/dL to 700–800 ng/dL over 6–9 months:
  • Reduce TMAO drivers by favoring whole-food patterns and supporting gut health.
  • Emphasize vitamin D and B vitamins if deficient.
  • Prioritize sleep and resistance training.
• Avoid exogenous testosterone if short-term fertility is a priority due to potential suppression of spermatogenesis.

References:

• Clomiphene for male hypogonadism and infertility (Ramasamy et al., 2014)
• Diet, TMAO, and cardiometabolic risk (Tang et al., 2013)

DCIS, Receptor Positivity, and Personalized Risk Dialogues

A critical language shift I encourage: ductal carcinoma in situ (DCIS) is a non-invasive, pre-cancerous condition, stage 0. While it warrants serious attention and individualized monitoring, equating DCIS with invasive cancer can produce overtreatment and fear. Receptors (estrogen, progesterone, and androgen) on cells are normal features; the presence of receptors alone does not imply a risk of malignancy without the appropriate cellular context.

Clinical reasoning:

• Standard oncology frameworks may recommend hormone suppression based on receptor positivity. In integrative conversations, we clarify that receptor presence is a physiological reality across tissues.
• The decision to use hormones post-treatment must consider time since treatment, current oncologic guidance, patient age, symptom burden, and tissue status (e.g., post-bilateral mastectomy vs. recent lumpectomy).

Personalized approach:

• In long-term survivors without breast tissue (e.g., bilateral mastectomy many years ago), estrogen may be reasonable to consider after informed consent, acknowledging benefits for vasomotor symptoms, bone, and cognition.
• In recent invasive cancer cases under active oncology care, I align with standard-of-care restrictions and focus on non-hormonal symptom support.

Documentation:

• Use informed consent waivers where appropriate to document patient preferences and acknowledgment of risk.

References:

• DCIS management and controversies (Narod, 2014)
• Hormone therapy risks/benefits post-breast cancer (Hulley et al., 2002)

Post-TIA Hormone Considerations and Neurology Myths

I regularly encounter myths linking any hormone therapy to stroke/TIA risk. The literature distinguishes between route, dose, and molecule. Transdermal or local therapies behave differently from oral systemic estrogens, and testosterone has distinct vascular effects.

Evidence-based points:

• Surgical menopause without estrogen replacement increases cardiovascular risk; appropriate estrogen therapy can mitigate some risks (Rocca et al., 2006).
• Transdermal estradiol is associated with lower thrombotic risk than oral estrogens due to reduced hepatic first-pass stimulation of clotting factors (Canonico et al., 2007).
• Testosterone in physiologic ranges does not uniformly increase stroke risk; careful monitoring of hematocrit is essential to reduce hyperviscosity risk.

Clinical strategy:

• After a TIA, the priority is vascular risk stratification: lipids, inflammation, sleep apnea, atrial fibrillation, and glucose control.
• If hormone therapy is considered, prefer transdermal routes, lowest effective doses, and concurrent lifestyle optimization.
• In some narratives, patients attribute events to therapy when underlying vascular risk was the driver; we carefully review timelines and objective markers.

References:

• Transdermal estrogen and thrombotic risk (Canonico et al., 2007)
• Surgical menopause and cardiovascular mortality (Rocca et al., 2006)

Immediate-Release vs. Extended-Release Medications

When asked whether I prefer immediate-release or extended-release for certain hormone-related medications, my clinical tendency favors immediate-release for flexibility and responsiveness, especially in symptom-driven titration (e.g., sleep quality with progesterone). Immediate-release formulations can produce stronger acute effects when desired, while extended-release formulations may blunt peaks and reduce variability.

Rationale:

• Immediate-release formulations allow more precise timing around symptoms (e.g., nighttime dosing for sleep).
• Extended-release formulations can be useful for steady-state needs but may delay symptom feedback loops that are critical to personalized care.

Endometriosis and Menopause: Why Progesterone Still Matters

For patients with past endometriosis entering menopause, progesterone remains important, even in those without a uterus. Microscopic endometrial-like implants can persist in pelvic tissues; progesterone helps suppress proliferation and counteract estrogenic stimulation.

Physiology:

• Endometrial implants maintain hormone responsiveness; progesterone opposes estrogen-driven growth and may reduce inflammatory signaling.
• Testosterone’s effect on endometriosis is limited; focus remains on progesterone for protective balance.

Clinical recommendations:

• Continue progesterone with estrogen therapy in postmenopausal women with a history of endometriosis, following ACOG guidance.
• Monitor symptoms and consider imaging if pain recurs.

Reference:

• Endometriosis management and hormone therapy (ACOG, 2023)

Thyroid Physiology: T4, Reverse T3, and Desiccated Options

A frequent scenario: a patient on levothyroxine (T4) doesn’t feel well, and labs show elevated reverse T3 (rT3). High rT3 often reflects stress physiology: the body converts T4 to rT3 to protect against hyperthyroidism under conditions like inflammation, caloric restriction, and illness.

Why rT3 rises:

• Deiodinase activity shifts under stress; D3 converts T4 to rT3, which is inactive and blocks T3 actions at the receptor.
• Single-bolus T4 dosing transiently increases serum T4, potentially triggering rT3 in sensitive individuals.

Clinical options:

• Consider desiccated thyroid (contains T1–T4 plus trace cofactors) or combination T4/T3 therapy to better match physiological signaling (Hoang et al., 2013).
• Adjust dose timing (split dosing) and address underlying inflammation, gut health, and nutrient cofactors (selenium, zinc, iron).
• Avoid excessive T3 dosing; target free T3 in the upper half of the normal range while respecting symptoms and heart rate.

Why it works:

• Combining T3 can overcome rT3 blockade at the receptor and improve metabolic rate.
• Desiccated preparations can feel more physiologic for some due to the multi-iodothyronine composition.

References:

• Desiccated thyroid vs. levothyroxine: patient-reported outcomes (Hoang et al., 2013)
• Deiodinases and thyroid hormone economy (Bianco & da Conceição, 2018)

Estriol vs. Estradiol: Skin, Receptors, and Expectations

Patients often ask about estriol (E3) creams for skin and urogynecologic support. Estriol is a weaker estrogen that preferentially binds estrogen receptor beta, potentially benefiting skin and mucosal tissues with lower systemic stimulation. Estradiol (E2) is more potent and better at controlling vasomotor symptoms.

Clinical insights:

• Estriol alone may not relieve hot flashes; combining low-dose estradiol can address systemic symptoms while maintaining localized benefits.
• Serum estrogen levels often remain unchanged with topical estriol; symptom relief is the primary metric.
• In peri- or postmenopausal care, titrate estradiol transdermally for symptom control and add local estriol for mucosal health when needed.

References:

• Estriol physiology and clinical use (Pickar et al., 2017)
• Transdermal estradiol benefits and safety (L’Hermite, 2013)

Hashimoto’s Optimization: When Free T3 Isn’t Enough

When a Hashimoto’s patient on levothyroxine has free T3 near 3.9 pg/mL but still feels unwell, I widen the lens. Many feel better when free T3 rises modestly above 4.0–4.5 pg/mL, but persistent symptoms often reflect gut inflammation, dysbiosis, food sensitivities, or viral reactivation.

Protocol steps:

• Verify the dosing schedule, absorption (avoid with calcium/iron), and consider split dosing.
• Evaluate gut health: stool studies, celiac serologies, SIBO breath testing as indicated.
• Optimize micronutrients (selenium 100–200 mcg, zinc, and iron repletion) and an anti-inflammatory diet.
• Consider switching to combination T4/T3 or desiccated thyroid if symptoms persist despite adequate labs.

Why it helps:

• Gut inflammation impairs absorption and increases cytokines that antagonize thyroid hormone signaling.
• Selenium supports deiodinase function and reduces TPO antibody titers in some patients (Gartner et al., 2002).

References:

• Hashimoto’s thyroiditis management (Antonelli et al., 2018)
• Selenium in autoimmune thyroiditis (Gartner et al., 2002)

High Creatinine With Normal Iron: Inflammation and Discovery

Occasionally, I see patients with elevated creatinine and normal iron indices, more commonly in men. Elevated creatinine can reflect muscle mass, dehydration, or early renal stress from inflammation and metabolic load, rather than overt kidney disease.

Clinical approach:

• Repeat measurements with adequate hydration.
• Check cystatin C for a muscle mass-independent assessment of GFR.
• Investigate systemic inflammation and metabolic drivers; high ferritin with normal transferrin saturation often indicates inflammatory signaling rather than iron overload.

Why discovery matters:

• Avoid reflexive pathology labeling; many elevations normalize when hydration and inflammation improve.
• Use structured questionnaires and clinical decision tools to guide next steps.

Reference:

• Assessing renal function: creatinine vs. cystatin C (Shlipak et al., 2013)

Integrative Chiropractic Care in Endocrine Treatment

Throughout my practice at Health Coach Clinic, integrative chiropractic care is central to optimizing endocrine and metabolic therapies. Here’s how:

Physiological pathways:

• Autonomic balance: Spinal adjustments influence sympathetic/parasympathetic tone, improving vagal activity, GI motility, and nutrient absorption.
• Neuroimmune crosstalk: Reducing nociceptive input lowers pro-inflammatory cytokines (IL-6, TNF-alpha), improving insulin sensitivity and thyroid hormone signaling.
• Biomechanics and breathing: Postural correction and thoracic mobility enhance respiratory efficiency and oxygen delivery, reducing fatigue and improving iron utilization.

Clinical observations:

• In women starting progesterone, addressing neck and thoracic tension reduces headaches and sleep disturbances.
• In men working to restore fertility, lumbar-pelvic mechanics and pelvic floor coordination improve circulation and autonomic stability.
• In Hashimoto’s, reducing musculoskeletal pain lowers stress hormones, thereby enhancing the effectiveness of thyroid medication.

For more, see my clinical work:

• healthcoach.clinic/
• www.linkedin.com/in/dralexjimenez/

References:

• Autonomic modulation and pain reduction (Yarnitsky, 2019)
• Vagal tone, inflammation, and metabolic health (Tracey, 2002)

Practical Points: Putting It All Together

• Iron
  • Check ferritin, transferrin saturation, CRP; treat root causes before loading iron.
  • Consider alternate-day iron; support gut for better absorption.
• Progestins and IUDs
  • Levonorgestrel IUDs offer local action with lower systemic risk.
  • Micronized progesterone often has better CNS tolerability.
• PCOS and progesterone
  • Use sublingual titration for sensitive patients; treat insulin resistance first.
• Cortisol
  • Use 4–5 point salivary profiles for rhythm; AM serum for screening.
• Male fertility
  • Short-term clomiphene for conception; prioritize lifestyle, avoid long-term SERMs.
• DCIS and receptors
  • Receptor presence is normal physiology; personalize risk conversations post-treatment.
• Post-TIA hormones
  • Prefer transdermal, lowest effective doses; address vascular risk first.
• Endometriosis in menopause
  • Keep progesterone even without a uterus due to residual implants.
• Thyroid
  • Address rT3 via inflammation control and consider T4/T3 combinations or desiccated thyroid.
• Estriol/Estradiol
  • Estriol is weak; combine with estradiol if vasomotor symptoms persist.
• Creatinine
  • Repeat with hydration; use cystatin C to clarify renal function.
• Integrative chiropractic
  • Improve autonomic tone, reduce inflammation, and enhance absorption to support endocrine therapies.

References

• Iron deficiency and related disorders

Camaschella, C. (2019). Iron deficiency. The New England Journal of Medicine, 381(12), 1148–1157.

• Hepcidin physiology and iron homeostasis

Ganz, T., & Nemeth, E. (2012). Hepcidin and iron homeostasis. Cell Metabolism, 15(6), 695–704.

• Alternate-day oral iron dosing improves absorption

Moretti, D., et al. (2015). Iron absorption from supplements is greater with alternate day than with consecutive day dosing. Blood, 126(23), 1981–1989.

• Iron status and performance in athletes

DellaValle, D. M. (2013). Iron supplementation in female athletes. Medicine & Science in Sports & Exercise, 45(9), 1807–1815.

• Contraceptive progestins and health effects

Dragoman, M. V., & Gaffield, M. E. (2016). The safety of levonorgestrel intrauterine devices. The Lancet.

• Micronized progesterone benefits

Prior, J. C. (2018). Progesterone for symptomatic menopausal women. Menopause International.

• PCOS pathophysiology and treatment

Azziz, R., et al. (2016). Polycystic ovary syndrome. The New England Journal of Medicine.

• Cortisol rhythms and assessment

Guilliams, T. G., & Williams, J. (2016). The assessment of hypothalamic-pituitary-adrenal axis function in clinical practice. The Journal of Clinical Endocrinology & Metabolism.

• Clomiphene for male hypogonadism and infertility

Ramasamy, R., et al. (2014). Clomiphene citrate in male infertility. The Journal of Urology.

• Diet, TMAO, and cardiometabolic risk

Tang, W. H. W., et al. (2013). Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. The New England Journal of Medicine.

• DCIS management and controversies

Narod, S. A. (2014). Ductal carcinoma in situ. The New England Journal of Medicine.

• Hormone therapy risks/benefits post-breast cancer

Hulley, S., et al. (2002). Estrogen in postmenopausal women after breast cancer. JAMA.

• Transdermal estrogen and thrombotic risk

Canonico, M., et al. (2007). Postmenopausal hormone therapy and venous thromboembolism: Impact of route of estrogen administration. Circulation.

• Surgical menopause and cardiovascular mortality

Rocca, W. A., et al. (2006). Premature menopause and risk of heart disease. Archives of Internal Medicine.

• Endometriosis management and hormone therapy

American College of Obstetricians and Gynecologists (ACOG). (2023). Endometriosis management.

• Desiccated thyroid vs. levothyroxine: patient-reported outcomes

Hoang, T. D., et al. (2013). Desiccated thyroid extract vs levothyroxine. The Journal of Clinical Endocrinology & Metabolism.

• Deiodinases and thyroid hormone economy

Bianco, A. C., & da Conceição, R. R. (2018). Thyroid hormone deiodinases. Physiological Reviews.

• Estriol physiology and clinical use

Pickar, J. H., et al. (2017). Estriol’s role in menopausal therapy. Climacteric.

• Transdermal estradiol benefits and safety

L’Hermite, M. (2013). Bioidentical hormones in menopause. Current Opinion in Oncology.

• Assessing renal function: creatinine vs. cystatin C

Shlipak, M. G., et al. (2013). Cystatin C vs. creatinine in kidney function. The New England Journal of Medicine.

• Autonomic modulation and pain reduction

Yarnitsky, D. (2019). Conditioned pain modulation. The Journal of Pain.

• Vagal tone, inflammation, and metabolic health

Tracey, K. J. (2002). The inflammatory reflex. Nature Reviews Neuroscience.